Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next year. Neogen

is likely to earn $1.30 per share in the next year ending May, 2014. Neogen's PEG ratio is 2.06. Abaxis

may earn $1.11 per share in the next year ending March, 2014. Abaxis' trailing-twelve-month operating margin is 12.95%. Trinity Biotech plc

is projected to earn $0.92 per share for the next year ending December, 2013. Trinity Biotech's trailing-twelve-month revenue is $80.67 million. Meridian Bioscience

is expected to earn $0.88 per share over the next year ending September, 2013. Meridian Bioscience's trailing-twelve-month ROE is 22.58%.